Protocols

Phase 2 and TRIUMPH-1 Phase 3 data show retatrutide's cardiometabolic burden is manageable at 9 mg but clinically meaningful at 12 mg in patients with pre-existing cardiac risk. The glucagon receptor-mediated heart rate increase is the primary signal. No oral formulation exists. The 9 mg dose is the evidence-supported inflection point where efficacy is maximised without disproportionate cardiometabolic cost.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending BPC-157, TB-500, KPV, and MOTS-c for the 503A bulk drug substances list. The committee cited absent human pharmacokinetic data, unresolved oncological signals for the angiogenic peptides, and no approved human indication for any of the four compounds as the primary evidentiary basis for each negative vote.

Rusfertide (PTG-300) is a synthetic hepcidin mimetic that suppresses erythropoiesis by blocking ferroportin-mediated iron export. In the Phase 2 REVIVE trial and the pivotal Phase 3 VERIFY trial, subcutaneous rusfertide eliminated or sharply reduced therapeutic phlebotomy requirements and maintained hematocrit below 45% in most polycythemia vera patients, establishing the strongest human evidence for iron restriction as a cytoreduction-independent disease-control strategy.

Gastric acid degrades oral semaglutide through direct acid-catalysed hydrolysis at pH 1 to 3 and through pepsin activation that cleaves semaglutide's backbone before it reaches absorptive epithelium. A 2026 review by Nayak, Dessai, and Nayak identifies acid protection as the central unsolved engineering challenge and proposes novel strategies to overcome it.

A 2026 Scientific Reports study and ADA 2026 proteomics data show that semaglutide attenuates cardiac ECM remodelling by restoring gut-barrier integrity and suppressing myocardial collagen deposition in obesity models, while a mortality-trained proteomic clock across SELECT and STEP cohorts found semaglutide 2.4 mg reduced multi-organ biological age by approximately 5.2% — with the largest effects in heart and kidney.

The 2026 Yuan review in International Journal of Molecular Sciences identifies three analgesic mechanisms in BPC-157 that operate independently of structural tissue repair: selective eNOS upregulation via the Src–Caveolin-1–eNOS pathway, suppression of TNF-α and IL-6 driving peripheral nociceptor sensitisation, and dose-dependent attenuation of neurogenic pain in formalin Phase 1 — a spinal-level effect separable from local wound healing.

The McGuire 2025 narrative review in Current Reviews in Musculoskeletal Medicine (18:611–619) concludes that BPC-157 demonstrates robust preclinical regenerative activity across muscle, tendon, ligament, bone, and cartilage — but that the absence of human clinical approval, an active FDA compounding ban, and unresolved oncological safety signals mean the compound sits in a genuine risk-benefit grey zone for practitioners in 2026.

The clearest human signal comes from Prasse et al. (2010), an open Phase 2 study in 20 histologically confirmed sarcoidosis patients: nebulized synthetic VIP (aviptadil) at 50 µg four times daily via ultrasonic nebulizer for 28 days significantly reduced TNF-α production by bronchoalveolar lavage (BAL) cells and expanded CD4+CD25+FoxP3+ regulatory T cells. No serious adverse events were recorded.

TRIUMPH-1 Phase 3 data show retatrutide dosed at 4 mg, 9 mg, or 12 mg once weekly via subcutaneous injection, escalated from a 2 mg starting dose over 20 weeks. The 12 mg arm produced 28.3% mean body-weight reduction at 80 weeks, exceeding tirzepatide's 22.5% ceiling at 15 mg in SURMOUNT-1, though no direct head-to-head trial has yet reported results.

A 2026 systems medicine review in Expert Review of Clinical Pharmacology synthesises major clinical trial data alongside proteomic and metabolomic evidence to map how semaglutide remodels inflammatory, lipid, and extracellular matrix (ECM) pathways across multiple organs. The picture that emerges is of a drug whose benefits extend well beyond glucose lowering and weight reduction into coordinated multi-system biology.

BRP (BRINP2-related peptide) is a naturally occurring 12-amino-acid peptide identified by Stanford researchers in 2025 using an AI-driven prohormone-cleavage prediction tool. It suppresses appetite via the hypothalamic cAMP–PKA–CREB–FOS cascade — a pathway entirely distinct from the GLP-1 receptor. Because BRP does not engage the area postrema, it produces equivalent food-intake reduction without triggering nausea or conditioned taste aversion.

Škrlec et al. (Applied Microbiology and Biotechnology, 2018) engineered Lactococcus lactis — a GRAS-status lactic acid bacterium — to produce and deliver BPC-157 via two strategies: cell-surface display with trypsin-mediated shedding, and direct secretion into the growth medium. The secretion strategy yielded superior antioxidant activity in cell-free supernatants, establishing L. lactis as a viable microbial chassis for oral BPC-157 delivery.